Sunesis Pharmaceuticals to Present Clinical Data at the 2006 Annual Meeting of the American Society of Clinical Oncology
May 31 2006 - 9:30AM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., May 31 /PRNewswire-FirstCall/ --
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that
the company will present data from its Phase I clinical studies of
SNS-595 during the upcoming 2006 Annual Meeting of the American
Society of Clinical Oncology (ASCO) being held in Atlanta, Georgia
June 2-6, 2006. The presentation of a poster, "SNS-595 demonstrates
clinical activity and dose-proportional pharmacokinetics (PK) in
two phase I clinical studies" (Abstract #3062), will take place on
Sunday, June 4, 2006 from 2:00 p.m. - 6:00 p.m. during the
Developmental Therapeutics: Molecular Therapeutics session. About
Sunesis' Oncology Programs Sunesis has built a portfolio of
preclinical- and development-stage product candidates in oncology
focused on novel pathways and targets, including inhibition of the
cell cycle and survival signaling. SNS-595 is a promising
first-in-class cancer therapeutic that selectively targets and
kills proliferating cells during the DNA replication phase of the
cell cycle. Currently in Phase II clinical development, SNS-595
works through the DNA-protein kinase and p73 dependent pathways to
induce apoptosis, or programmed cell death. SNS-032 is in a Phase
I/II clinical study to examine the safety and preliminary
anti-tumor activity among patients with a variety of solid tumors,
including lung cancer, breast cancer or melanoma. SNS-032 is a
potent and selective inhibitor of cyclin-dependent kinases 2, 7 and
9. Sunesis is currently conducting preclinical studies of its
Aurora kinase inhibitor drug candidate, SNS-314. In addition, in
cooperation with Biogen Idec, Sunesis is developing novel small
molecule inhibitors of Raf kinase and other oncology kinases. About
Sunesis Pharmaceuticals Sunesis is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel small molecule therapeutics for oncology
and other serious diseases. Sunesis has built a broad product
candidate portfolio through internal discovery and in-licensing of
novel cancer therapeutics. Sunesis is advancing its product
candidates through in-house research and development efforts and
strategic collaborations with leading pharmaceutical and
biopharmaceutical companies. Forward-Looking Statements This press
release may contain forward-looking statements that involve
substantial risks and uncertainties. Sunesis may not actually
achieve the plans, intentions or expectations contained in such
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations contained in
such forward-looking statements. Sunesis does not assume any
obligation to update any such forward-looking statements. For
further information on Sunesis Pharmaceuticals, please visit
http://www.sunesis.com/. DATASOURCE: Sunesis Pharmaceuticals, Inc.
CONTACT: investors, Eric Bjerkholt, CFO, of Sunesis
Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman,
or Michelle Corral, both of BCC Partners, +1-650-575-1509, or
+1-415-794-8662, for Sunesis Pharmaceuticals, Inc. Web site:
http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024